Sienna Biopharmaceuticals (SNNA) IPO Opens Sharply Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
July 26, 2017 7:30 PM EDTWESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) today announced the pricing of the Companys initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares of common stock are being offered by Sienna. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 650,000 shares of common stock at the initial public offering price, less the underwriting discount. Siennas common stock has been approved for listing... More
